Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib Combined With Realgar-Indigo Naturalis Formula (RIF) in Treating Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation
NCT04232722Phase 2Unknown
- Sponsor
- Zhejiang University
- Start
- Jan 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of Compound Huangdai Tablet in hepatocellular carcinoma (HCC), sponsored by Zhejiang University. Status: unknown.
02
Drugs
Compound Huangdai Tablet
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04232722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04232722.